Rocket Lab Director Sells $210K in Stock Through Planned Trading Program

Rocket Lab Corp director Merline Saintil executed two planned sales transactions on June 24, 2025, disposing of a total of 6,353 shares of common stock through a pre-established Rule 10b5-1 trading plan from March 20, 2025.

Rhea-AI Filing Summary

Rocket Lab Corp director Merline Saintil executed two planned sales transactions on June 24, 2025, disposing of a total of 6,353 shares of common stock through a pre-established Rule 10b5-1 trading plan from March 20, 2025.

Transaction details:

• First sale: 4,053 shares at weighted average price of $33.1473 (range: $32.51-$33.50)
• Second sale: 2,300 shares at weighted average price of $33.7848 (range: $33.51-$34.13)
• Remaining direct ownership: 419,569 shares

The transactions were executed according to a predetermined trading plan, which provides an affirmative defense against insider trading allegations. The sales were reported within the required two-business-day filing deadline.

Insider Trade Summary

Net Seller: 6,353 shares

Net Sell 2 txns

Insider Saintil Merline

Role Director

Sold 6,353 shs ($212K)

Type	Security	Shares	Price	Value
Sale	Common Stock	4,053	$33.1473	$134K
Sale	Common Stock	2,300	$33.7848	$78K

Holdings After Transaction: Common Stock — 419,569 shares (Direct)

Footnotes (3)

1. F1. Represents the sale of shares which occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 20, 2025.
2. F2. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.5100 to $33.5000, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
3. F3. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.5100 to $34.1300, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

FAQ

How many RKLB shares did Director Merline Saintil sell on June 24, 2025?

Director Merline Saintil sold a total of 6,353 shares of RKLB common stock on June 24, 2025, consisting of 4,053 shares at an average price of $33.1473 and 2,300 shares at an average price of $33.7848.

What was the price range of RKLB shares sold by Director Saintil?

The shares were sold in multiple transactions at two price ranges: 4,053 shares were sold between $32.51 and $33.50, and 2,300 shares were sold between $33.51 and $34.13.

How many RKLB shares does Merline Saintil own after the June 24, 2025 transactions?

Following the reported transactions, Merline Saintil directly owns 419,569 shares of Rocket Lab (RKLB) common stock.

Was RKLB Director Saintil's stock sale part of a pre-planned trading arrangement?

Yes, the sales occurred automatically pursuant to a Rule 10b5-1 trading plan that was adopted by Merline Saintil on March 20, 2025.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/25/2025 - 04:05 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Saintil Merline

(Last) (First) (Middle)

C/O ROCKET LAB CORPORATION

3881 MCGOWEN STREET

(Street)

LONG BEACH CA 90808

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Rocket Lab Corp [ RKLB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
06/24/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/24/2025		S		4,053(1)	D	$33.1473(2)	421,869	D
Common Stock	06/24/2025		S		2,300(1)	D	$33.7848(3)	419,569	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents the sale of shares which occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 20, 2025.

2. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.5100 to $33.5000, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

3. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.5100 to $34.1300, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

	/s/ Arjun Kampani as Attorney-in-Fact for Merline Saintil	06/25/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.